FinancialContent is the trusted provider of stock market information to the media industry.
Orexigen Climbs On Locaserin's Approval

Shares of Orexigen Therapeutics Inc. (Nasdaq: OREX) climbed again by gaining 84 cents to $5.76 after rival Arena Pharmaceuticals Inc.'s (Nasdaq: ARNA) weight loss treatment Lorcaserin was approved yesterday. Arena stock dropped $1.29 to $10.10 as investors locked in profits on the biopharmaceutical.

Stock Market JSON API provided by
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More